EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the ...

Throughout the last three months, 4 analysts have evaluated EyePoint Pharmaceuticals (NASDAQ:EYPT), offering a diverse set of opinions from bullish to bearish. The table below summarizes their recent ...

EyePoint Pharmaceuticals (NASDAQ:EYPT) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below provides a concise overview of ...

WATERTOWN, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of ...

(Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted ...

WATERTOWN, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with ...

EyePoint Pharmaceuticals, Inc. EYP-1901, a potential treatment for wet age-related macular degeneration, showed positive results in a Phase 2 study, meeting primary and secondary endpoints. The drug ...

EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT) stock is trading higher on Monday after the company revealed interim 16-week data from the ongoing Phase 2 VERONA trial of Duravyu for patients with ...

EyePoint reported top-line data on two phase 2 trials for its lead pipeline candidate. The company focuses on serious eye disorders. It said it has enough cash to fund operations into 2025. EyePoint ...

A Relative Strength Rating upgrade for EyePoint shows improving technical performance.

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. More than 400 patients have been enrolled in the LUCIA ...

– Seasoned commercial executive with over 30 years of leadership in retinal disease across biotech and large pharma – – Brings established track record of successful product launches and oversight of ...